Beecham Group Plc

Societe De Conseils De Recherches Et D'applications Scientifiques Sas

Biomeasure Incorporated

Ipsen Pharma S.a.s.

Michael Anthony Cawthorne

Matthew V Sennitt

Yong-Ling Liu

Simon Jon Dunmore

Michelle Davenport

Joseph Green

The present invention relates to a method of decreasing body weight in a patient. The method includes the step of administering a therapeutically effective amount of a somatostatin or a somatostatin agonist to said patient. A pharmaceutical/cosmetic composition comprises the somatostatin or somatostatin agonist. Such products are used to prepare such compositions for the reduction or body weight in a human or mammalian animal.

Method for decreasing body weight using a somatostatin receptor agonist

The present invention relates to a method of treating insulin resistance or Syndrome X by administering a therapeutically effective amount of a somatostatin agonist or a pharmaceutical composition comprised of a somatostatin agonist to a patient suffering from insulin resistance or Syndrome X.

Somatostatin and somatostatin agonists for treating insulin insensitivity and Syndrome X

The present invention relates to a method of decreasing body weight in a patient. The method includes the step of administering a therapeutically effective amount of a somatostatin or a somatostatin agonist to said patient. A pharmaceutical/cosmetic composition comprises the somatostatin or somatostatin agonist. Such products are used to prepare such compositions for the reduction of body weight in a human or mammalian animal.

Somatostatin and somatostatin agonists for decreasing body weight

The present invention relates to a method of treating hyperlipidemia and to reducing triacylglycerols, glycerol and cholesterol in a patient. The method includes the step of administering a therapeutically effective amount of a type-5 selective somatostatin agonist to said patient. A pharmaceutical composition comprises said agonist and such product is used in the preparation of the composition for use in treating hyperlipidemia or reducing triacylglycerols, glycerol and cholesterol in a patient's body.

Method and compositions for treating hyperlipidemia and other conditions

A method of determining the ability of a compound to both bind to somatostatin type-5 receptor (&ldquo;SSTR-5&rdquo;) and inhibit amylin release. The method includes obtaining a preparation, either a cell preparation or a membrane preparation, which contains SSTR-5; incubating the preparation, the compound, and a SSTR-5 ligand, at least one of the ligand and the compound being detectably labeled; determining the ability of the compound to compete against the ligand for binding to SSTR-5; if and only if the compound is determined to be able to bind to SSTR-5, obtaining pancreatic cells; incubating the compound, the pancreatic cells, and an amylin release stimulator under conditions in which the amylin release stimulator would induce release of amylin from the pancreatic cells; and determining the ability of the compound to inhibit amylin release. Also disclosed is a method of treating hyperamylinemia with a ligand selective for SSTR-5.

Inhibition of amylin release

The present invention relates to a method of decreasing body weight in a patient. The method includes the step of administering a therapeutically effective amount of a type-5 selective somatostatin agonist to the patient.

Method of treating hyperlipidemia

A method of determining the ability of a compound to both bind to somatostatin type-5 receptor ('SSTR-5') and inhibit amylin release. The method includes obtaining a preparation, either a cell preparation or a membrane preparation, which contains SSTR-5; incubating the preparation, the compound, and a SSTR-5 ligand, at least one of the ligand and the compound being detectably labeled; determining the ability of the compound to compete against the ligand for binding to SSTR-5; if and only if the compound is determined to be able to bind to SSTR-5, obtaining pancreatic cells; incubating the compound, the pancreatic cells, and an amylin release stimulator under conditions in which the amylin release stimulator would induce release of amylin from the pancreatic cells; and determining the ability of the compound to inhibit amylin release. Also disclosed is a method of treating hyper-amylinemia with a ligand selective for SSTR-5.

A method for the treatment and/or prophylaxis of hyperglycaemia in human or non-human mammals which comprises administering to the mammal in need of such treatment and/or prophylaxis an effective non-toxic amount of: a compound of formula (I): ##STR1## or a pharmaceutically acceptable acid additon salt thereof, wherein each of R.sup.1 and R.sup.2, which may be the same or different, represents a hydrogen or haolgen atom, or an alkyl or alkoxy group containing 1 to 4 carbon atoms, X represents an oxygen or sulphur atom, an imino group, an acylimino group containing 2 to 4 carbon atoms in the acyl group, or a methylene group, each of n and m, which may be the same or different, represents the number 1, 2 or 3, and p represents the number 2 or 3.

Treatment for hyperglycaemia

A method for the treatment and/or prophylaxis of hyperglycemia in mammals including administration to the mammal of an effective, nontoxic amount of either a compound of formula (I), ##STR1## or a pharmaceutically acceptable acid addition salt thereof; or of a compound of formula (II), ##STR2## or a pharmaceutically acceptable acid addition salt thereof.

Novel treatment of hyperglycaemia

A method for the treatment and/or prophylaxis of hyperglycaemia in human or non-human mammals which comprises administering to the mammal in need of such treatment and/or prophylaxis an effective non-toxic amount of:

Novel treatment

Fibrinolytic pharmaceutical compositions are provided in unit dosage form and comprise a water-soluble complex of a proteolytic enzyme linked covalently to a polymeric substance.

Growing community of inventors

Horsham, United Kingdom

Michael Anthony Cawthorne